Status:
COMPLETED
Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study
Lead Sponsor:
Ain Shams University
Conditions:
Methotrexate Spermatotoxicity
Eligibility:
MALE
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this study is to assess the potential protective role of selenium on semen parameters and its effect on seminal glutathione peroxidase level in patients on MTX therapy
Detailed Description
The aim of this study is to assess the potential protective role of selenium on semen parameters and its effect on seminal glutathione peroxidase level in patients on MTX therapy. informed consent was...
Eligibility Criteria
Inclusion
- adult males from 18-60 years old for the 2 methotrexate (MTX) study groups, the males included were chosen from patients already planned to start MTX treatment for psoriasis
Exclusion
- History of drug intake that can affect semen parameters i.e., cytotoxic drugs, anti-androgens, sulfasalazine, gonadal hormones, nitrofurans or salicylic acid within previous three months.
- History of smoking within the last three months.
- Chronic disorders such as diabetes mellitus, hypertension, obesity, chronic liver or renal disease.
- Organic diseases that can affect fertility i.e., varicocele, testicular tumor or undescended testis.
- Genitourinary diseases.
Key Trial Info
Start Date :
May 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06951282
Start Date
May 2 2024
End Date
December 31 2024
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Abbassia, Egypt, 00202